Krystal Biotech (4KB) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Kb803 | Recessive Dystrophic Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa, Deb - Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa | Phase III | Recruiting | A Study Assessing KB803 Compared to Matching Placebo for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis Bullosa | May 27, 2025 | ― |
| Kb801 | Neurotrophic Keratitis | phase1AndPhase2 | Recruiting | A Study Assessing KB801 for the Treatment of Stage 2 or 3 Neurotrophic Keratitis | May 14, 2025 | ― |
| Kb304, 0.9% Normal Saline (Ns) | Wrinkles In Decolletage, Pigmentation, Décolleté Wrinkles | phase1AndPhase2 | Active Not Recruiting | A Study Assessing KB304 for the Treatment of Wrinkles in Women | Dec 05, 2024 | ― |
| Docetaxel, Chemotherapy, Pembrolizumab (Keytruda®), Kb707 | Advanced Cancer, Solid Tumor, Adult, Lung Cancer, Non-Small Cell, Lung Cancer Metastatic, Lung Cancer (Nsclc) | phase1AndPhase2 | Recruiting | A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | Jan 18, 2024 | ― |
| Kb408 (Nebulization) | Alpha 1-Antitrypsin Deficiency | Phase I | Recruiting | A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency | Sep 15, 2023 | ― |
| Kb707, Opdualag, Keytruda ®( Pembrolizumab) | Cancer, Cutaneous Melanoma, Melanoma Stage Iii, Melanoma Stage Iv | phase1AndPhase2 | Recruiting | A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | Jul 24, 2023 | ― |
| Kb407 (Nebulization) | Cystic Fibrosis | Phase I | Recruiting | A Study Assessing KB407 for the Treatment of Cystic Fibrosis | Aug 15, 2022 | ― |
| Kb301 | Wrinkle, Skin Roughness, Fine Lines, Skin Thickness | Phase I | Active Not Recruiting | A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions | Aug 19, 2020 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Kb803 | Phase III | Recessive Dystrophic Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa, Deb - Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa | Recruiting | A Study Assessing KB803 Compared to Matching Placebo for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis Bullosa | May 27, 2025 | ― |
| Kb801 | phase1AndPhase2 | Neurotrophic Keratitis | Recruiting | A Study Assessing KB801 for the Treatment of Stage 2 or 3 Neurotrophic Keratitis | May 14, 2025 | ― |
| Kb304, 0.9% Normal Saline (Ns) | phase1AndPhase2 | Wrinkles In Decolletage, Pigmentation, Décolleté Wrinkles | Active Not Recruiting | A Study Assessing KB304 for the Treatment of Wrinkles in Women | Dec 05, 2024 | ― |
| Docetaxel, Chemotherapy, Pembrolizumab (Keytruda®), Kb707 | phase1AndPhase2 | Advanced Cancer, Solid Tumor, Adult, Lung Cancer, Non-Small Cell, Lung Cancer Metastatic, Lung Cancer (Nsclc) | Recruiting | A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | Jan 18, 2024 | ― |
| Kb408 (Nebulization) | Phase I | Alpha 1-Antitrypsin Deficiency | Recruiting | A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency | Sep 15, 2023 | ― |
| Kb707, Opdualag, Keytruda ®( Pembrolizumab) | phase1AndPhase2 | Cancer, Cutaneous Melanoma, Melanoma Stage Iii, Melanoma Stage Iv | Recruiting | A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | Jul 24, 2023 | ― |
| Kb407 (Nebulization) | Phase I | Cystic Fibrosis | Recruiting | A Study Assessing KB407 for the Treatment of Cystic Fibrosis | Aug 15, 2022 | ― |
| Kb301 | Phase I | Wrinkle, Skin Roughness, Fine Lines, Skin Thickness | Active Not Recruiting | A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions | Aug 19, 2020 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Krystal Biotech, Inc. (DE:4KB) have in its pipeline
Krystal Biotech DE:4KB is currently developing the following drugs: Kb803, Kb801, Kb304, 0.9% Normal Saline (Ns), Docetaxel, Chemotherapy, Pembrolizumab (Keytruda®), Kb707, Kb408 (Nebulization), Kb707, Opdualag, Keytruda ®( Pembrolizumab), Kb407 (Nebulization), Kb301. These drug candidates are in various stages of clinical development as the company works toward FDA approval.